R

Regulus Therapeutics
D

RGLS

1.59000
USD
0.04
(2.58%)
Market Closed
Volume
0
EPS
-1
Div Yield
-
P/E
-2
Market Cap
104,145,213
OverviewSignalsIdeasNews
Related Instruments
    A
    ARWR
    -0.020
    (-0.10%)
    19.450 USD
    A
    AXSM
    1.160
    (1.29%)
    90.840 USD
    C
    CRSP
    0.360
    (0.89%)
    40.720 USD
    D
    DVAX
    -0.020
    (-0.16%)
    12.720 USD
    E
    EDIT
    -0.01000
    (-0.75%)
    1.32000 USD
    F
    FOLD
    0.07500
    (0.77%)
    9.81000 USD
    I
    IONS
    0.040
    (0.11%)
    35.630 USD
    S
    SRPT
    -0.470
    (-0.39%)
    118.970 USD
    V
    VKTX
    0.780
    (1.88%)
    42.270 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    More
News

Title: Regulus Therapeutics

Sector: Healthcare
Industry: Biotechnology
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.